Navigation Links
Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call

CARY, N.C., Oct. 28 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX) today announced that it will host a conference call at 4:30 PM ET on Thursday, November 4, 2010, to discuss its financial results for the quarter and nine months ended September 30, 2010. Financial results are expected to be released on Thursday, November 4, 2010, after the capital markets close.

To participate in the live conference call, please dial 866-804-6927 (U.S. callers) or 857-350-1673 (international callers), and provide passcode 19358387. A live webcast of the call will also be available through the Investor Relations section of the Company's website. Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The conference call and the webcast will be archived for 30 days.  The telephone replay of the call will be available at 7:30 PM ET on November 4, 2010 by dialing 888-286-8010 (U.S. callers) or 617-801-6888 (international callers), and providing passcode 43083287.

About Cornerstone TherapeuticsCornerstone Therapeutics Inc. (Nasdaq: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians, key retail pharmacies and hospitals with its specialty sales forces. The Company also has a late-stage clinical pipeline with a recent regulatory submission filing and four additional regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory or related pharmaceutical products, or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales forces; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Safe Harbor Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein, other than statements of historical fact, including statements regarding the progress and timing of our product development programs and related trials, our strategy and our future operations and opportunities, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of preclinical studies and clinical trials with respect to our products under development, our ability to satisfy FDA and other regulatory requirements and the other factors described in Item 1A (Risk Factors) of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 4, 2010 and in our subsequent filings with the SEC. In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release, should not be relied upon as representing our views as of any other date and do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make or enter into. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise. CONTACT: Investor Relations Contacts: Westwicke PartnersJohn Woolford+1-443-213-0506john.woolford@westwicke.comWestwicke PartnersStefan Loren, Media Relations Contact:Fleishman-HillardAndrea

SOURCE Cornerstone Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cornerstone Therapeutics Announces Development of Generic for Tussionex®
2. Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept
3. Cornerstone Therapeutics Announces Collaboration with The Cough Company
4. Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
5. Cornerstone Therapeutics Announces Management Change
6. Cornerstone Therapeutics To Present at Deutsche Banks 35th Annual Healthcare Conference
7. Cornerstone Therapeutics to Host First Quarter 2010 Conference Call
8. Cornerstone Therapeutics to Present at the 30th Annual Cowen & Company Health Care Conference
9. Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010
10. Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal
11. Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... that immunotherapy can be efficiently combined with photodynamic therapy ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Japanese therapeutic drug monitoring market, including ...
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Care Market by Type (Dressings, Therapy Devices, Active Wound ... Out-Patient Facility), and Geography - Global Forecast to 2020" ... --> --> The purpose of this ... of the global advanced wound care market. It involves ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion ... off of their purchase of lice treatment product. In addition, customers will receive a ... company spokesperson. “Finding lice is a sure way to ruin the holidays, so we ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... progress through sharing, the 2016 Building Better Radiology Marketing Programs meeting ... begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas with ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in ... for mental health and wellness consultation, has collaborated with a leading web-based marketplace ... knowledge gap experienced by parents and bring advice from parenting experts within their ...
(Date:11/27/2015)... , ... November 27, 2015 , ... Avid collector, Andrew ... Arbor Michigan boxing style concert posters. This is one of Joplin's most famous and ... House at the University of Michigan in Ann Arbor. The According to Hawley, "It ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, ... Medicine tests directly from their electronic medical record (EMR) without the need for ...
Breaking Medicine News(10 mins):